期刊文献+

表达HIV-1 B亚型env基因的质粒DNA及腺病毒载体疫苗的免疫原性研究 被引量:4

Immunogenicity of plasmid DNA and adenoviral vectors encoding HIV-1 subtype B env gene
原文传递
导出
摘要 目的 构建表达中国B亚型HIV-1流行株env基因的DNA及重组腺病毒载体疫苗,将其用于预防或治疗HIV感染.方法 构建质粒DNA疫苗pVR-gp160及重组腺病毒载体疫苗rAdV-gp160.将这两种疫苗以不同的方式免疫BALB/c小鼠,分别采用ELISPOT方法 和ELISA方法 检测免疫小鼠中HIV-1 Gp120特异性细胞免疫反应及抗体反应.结果 DNA疫苗单独免疫及DNA疫苗初免/腺病毒疫苗加强免疫的联合免疫方案皆可诱导较高水平的Gp120特异性细胞免疫反应;而在体液免疫方面,各实验组产生的Gp120特异性抗体水平都较低.结论 所构建的DNA疫苗及rAdV疫苗能有效表达Gp160蛋白,并可有效激活机体的细胞免疫反应. Objective To construct DNA and recombinant adenovirus vector vaccines containing an env gene from the prevalent subtype B strain in China and try to use them for therapeutic and prophylactic vaccines. Methods The candidate plasmid DNA vaccine pVR-gp160 and recombinant adenovirus vaccine rAdV-gp160 were constructed separately. BALB/c mice were immunized with these two vaccines in different administration schemes. HIV-1 Gp120-specific cellular responses and antibody levels were detected by ELISPOT and ELISA respectively. Results DNA vaccine alone and combined vaccines in a DNA prime/rAdV-gp160 boost vaccination regimen induced high level of Gp120-specific cellular responses. While low level of Gp120-specific antibodies were elicited in all groups. Conclusion DNA and rAdV vaccines could efficiently express Gp160 protein and activate specific cellular responses.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2010年第6期415-417,共3页 Chinese Journal of Experimental and Clinical Virology
基金 国家重大科技专项(2008ZX10001-009) 国家自然科学基金(30872397)
关键词 艾滋病疫苗 基因 env 质粒 腺病毒科 AIDS vaccines Genes, env Plasmids Adenoviridae
  • 相关文献

参考文献4

  • 1Schoenly KA,Weiner DB.Human immunodeficiency virus type 1 Vaccine Development:Recent Advances in the CTL Platform "Spotty Business".J Virol,2008,82:3166-3180.
  • 2Cox KS,Clair JH,Prokop MT,et al.DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.J Virol,2008,82:8161-8171.
  • 3Yu SQ,Feng X,Shu T,et al.Potent specific immune responses induced by prime-boost-boost strategies based on DNA,adenovirus,and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.Vaccine,2008,26:6124-6131.
  • 4冯霞,杨海儒,余双庆,周玲,李红霞,李泽琳,曾毅.河南省有偿供血者HIV-1外膜蛋白env基因序列分析及表型预测[J].病毒学报,2009,25(2):88-94. 被引量:5

二级参考文献17

  • 1崔为国,邢辉,王哲,黄海龙,李宏,薛晓玲,朱新朋,邵一鸣.河南省艾滋病毒I型膜蛋白基因序列特征和亚型研究[J].河南预防医学杂志,2005,16(1):3-5. 被引量:5
  • 2Zwick MB, Jensen R, Church S, et al, Anti-human immunodeficiency virus type 1 ( HIV-1 ) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membraneproximal external region of glycoprorein gp41 to neutralize HIV-1 [J]. J Virol, 2005, 79 (2) : 1252-1261.
  • 3Zwick M B, Labrijn A F, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41 [J]. J Virol, 2001, 75 (22): 10892-10905.
  • 4http://www, gov. cn/xwfb/2008-11/30/content 1164167. htm[EB].
  • 5Robertson D L, Anderson J P, Bradac J A, et al. HIV- 1 nomenclature proposal [J]. Science, 2000, 288 (5463) : 55-56.
  • 6Su B, Liu L, Wang F, et al. HIV-1 subtype B dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China [J]. Aids, 2003, 17(17): 2515-2520.
  • 7http://www, hiv. lanl. gov/content/sequence/GLY- COSITE/glycosite. html[EB].
  • 8Wei X, Decker J M, Wang S, et al. Antibody neutralization and escape by HIV-1[J]. Nature, 2003, 422 (6929) : 307-312.
  • 9Scanlan C N, Pantophlet R, Wormald M R, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alphal→2 mannose residues on the outer face of gp120 [-J~. J Virol, 2002, 76(14): 7306-7321.
  • 10Kwong P D, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody [J]. Nature, 1998, 393(6686): 648-659.

共引文献4

同被引文献33

  • 1臧春鹏,汪宁.抗病毒治疗在阻断艾滋病传播流行中的作用[J].中华临床医师杂志(电子版),2011,5(8):2343-2346. 被引量:18
  • 2Excler JL, Robb ML, Kim JH. HIV-1 vaccines: Challenges and new perspectives [ J ]. Hum Vaccin Immunother,2014,10 (6).
  • 3Enama ME, Ledgerwood JE, Novik L. Phase I Randomized Clini- cal Trial of VRC DNA and rAd5 H1V-1 Vaccine Delivery by In- tramuscular ( IM ) , Subcutaneous ( SC ) and lntradermal ( ID ) Administration ( VRC 011) [ J ]. PLoS One,2014,9(3) :e91366.
  • 4Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNAZrAd5 HIV-1 preventive vaccine[J]. N Engl J Med,2013, 369 ( 22 ) : 2083 -92.
  • 5Muthumani K,Wise MC, Broderick KE HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B-and T-cell respon- ses and neutralizing phenotype in vivo [ J ]. PLoS One, 2013,8 (12) : e84234.
  • 6Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand [J]. N Engl J ned,2007,361 (23) :2209-2220.
  • 7Haynes BF, Gilbert PB, McElrath M J, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trlal[J]. N Engl J Med, 2012,366(14) : 1275-86.
  • 8Morgane R,Paul TE, Brendan BL,et al. Increased HIV-1 vaccine efficacy against viruses with geneticsignatures in Env V2[ J ]. Na- ture ,2012 ;490:417-420.
  • 9Yu S, Feng X, Shu T,et al. Potent specific immune responses in- duced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-I subtype B[J]. Vaccine,2008,26(48) :6124-31.
  • 10Zak DE1, Andersen-Nissen E, Peterson ER, et al. Merck AdS/ HIV induces broad innate immune activation that predicts CD8 T-ceU responses but is attenuated by preexisting AdS immunity [J]. Proc Nail Acad Sci USA,2012,109(50):3503-12.

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部